Press Releases Ipsen

Equities

IPN

FR0010259150

Pharmaceuticals

Real-time Euronext Paris Other stock markets 12:36:02 10/03/2026 +03			5-day change	1st Jan Change
161.50 ^EUR	+4.73%		+0.44%	+35.71%

03-09	Hutchmed (China) says Ipsen initiates market withdrawal and recall of Tazverik in China	RE
03-09	Hutchmed announces update on licensed oncology product Tazverik in China	RE

Press Releases

03-09	Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma	AQ
03-09	Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma	GL
02-27	Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma	GL
02-19	Ipsen S.A. publishes its 2025 Consolidated Financial Statements	GL
02-12	Ipsen : FY 2025 – Presentation (1.44 MB)	PU
02-12	Ipsen : FY 2025 – Highlights (340.30 KB)	PU
02-12	Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance	GL
02-12	Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance	AQ
01-30	Ipsen : expands pre-clinical pipeline in rare neurodegenerative diseases	PU
01-29	Ipsen nominates Peter Guenter to its Board of Directors	GL
01-27	Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership Team	GL
01-27	Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership Team	AQ
01-22	Arbitration tribunal upholds Ipsen's termination of R&D agreement with Galderma	AQ
01-21	Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma	GL
01-15	New data reinforces Ipsen's commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS	AQ
01-14	U.S. FDA grants Ipsen's IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia	AQ
01-14	New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS	GL
01-13	U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia	GL
01-09	Ipsen : Statement on Lanreotide Generic Supply Challenges	PU
01-06	Ipsen – Half year statement – 2025 12 31	GL
12-23	Ipsen expands early development pipeline with Simcere Zaiming's innovative antibody drug conjugate	AQ
12-22	Ipsen : Université de Montréal and IRICoR expand long-term partnership to accelerate early-stage oncology innovations	PU
12-22	Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate	GL
12-19	Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)	GL
12-15	Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline	GL